0000000000620638

AUTHOR

Stefan Schneeberger

showing 4 related works from this author

Should kidney allografts from old donors be allocated only to old recipients?

2020

Contains fulltext : 226016.pdf (Publisher’s version ) (Closed access) In several deceased donor kidney allocation systems, organs from elderly donors are allocated primarily to elderly recipients. The Eurotransplant Senior Program (ESP) was implemented in 1999, and since then, especially in Europe, the use of organs from elderly donors has steadily increased. The proportion of ≥60-year-old donors reported to the Collaborative Transplant Study (CTS) by European centers has doubled, from 21% in 2000-2001 to 42% in 2016-2017. Therefore, in the era of organ shortage it is a matter of debate whether kidney organs from elderly donors should only be allocated to elderly recipients or whether <65-y…

medicine.medical_specialtyTissue and Organ ProcurementMedizinEconomic shortage030230 surgeryKidneyold donors03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIncreased creatininemedicineHumanskidney allograftsAgedDeceased donor kidneyKidneyTransplantationbusiness.industryGraft SurvivalAge FactorsCancerMiddle Agedmedicine.diseaseAllograftsKidney TransplantationTissue DonorsEuropekidney allografts ; old donors ;Marginal donormedicine.anatomical_structureDonation030211 gastroenterology & hepatologyRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]business
researchProduct

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

2019

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently b…

0301 basic medicinePulmonary and Respiratory MedicineRiskScoring systemmedicine.medical_treatmentMedizinVascular complicationLiver transplantationEnd Stage Liver Disease03 medical and health sciences0302 clinical medicineSevere hypoxemiaNothingMedicineHumansRegistriesProportional Hazards ModelsRetrospective Studiesbusiness.industryConflict of interestTreatment optionsLiver TransplantationEuropeOxygen030104 developmental biologyTreatment OutcomeLaw030211 gastroenterology & hepatologybusinessProduction teamHepatopulmonary SyndromeThe European respiratory journal
researchProduct

Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis

2020

Transplant international (2020). doi:10.1111/tri.13569

re-transplantationOutcome analysis030230 surgeryKidneyALLOCATION0302 clinical medicine3RDfourthKidney transplantationKidneychildGraft SurvivalConfoundinglossSUCCESSrepeatedGRAFT LOSSCOMPETING RISKSTissue Donorsddc:Treatment Outcomesurgical procedures operativemedicine.anatomical_structure030211 gastroenterology & hepatologyOutcome dataLife Sciences & Biomedicinemedicine.medical_specialtykidneyTissue and Organ ProcurementRe transplantation610survival1ST03 medical and health sciencesmedicineHumansddc:6102NDRetrospective StudiesDeceased donorTransplantationScience & Technologybusiness.industrymedicine.diseaseKidney TransplantationSurgeryTransplantationRECIPIENTSgraftSurgeryHuman medicinebusinessthirdSINGLE-CENTER
researchProduct

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct